Literature DB >> 2865642

Inactivation of HTLV-III/LAV during plasma fractionation.

D Piszkiewicz, H Kingdom, R Apfelzweig, J S McDougal, S P Cort, J Andrews, J Hope, C D Cabridilla.   

Abstract

Mesh：

Year:  1985        PMID： 2865642     DOI： 10.1016/s0140-6736(85)92710-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Hemophilia-associated AIDS in the United States, 1981 to September 1987.

Authors:  J K Stehr-Green; R C Holman; J M Jason; B L Evatt
Journal:  Am J Public Health       Date:  1988-04       Impact factor: 9.308

Review 2.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

Review 4.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.